Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 8/20 | 0.66 |
| ▸ | MMP2 | P08253 | 8/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.66 |
| ▸ | MMP9 | P14780 | 6/20 | 0.66 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365923 | 1.00 | ADAM10 (0.66) | ADAM10MMP2ERBB2MMP9GRM5 | |
| SCHEMBL1365259 | 0.83 | ADAM10 (0.78) | ADAM10MMP2ERBB2MMP9CTSB | |
| SCHEMBL1365260 | 0.83 | ADAM10 (0.78) | ADAM10MMP2ERBB2MMP9CTSB | |
| SCHEMBL5131030 | 0.83 | ADAM10 (0.78) | ADAM10MMP2ERBB2MMP9CTSB | |
| SCHEMBL1365880 | 0.81 | FABP7 (0.45) | KMT2A | |
| SCHEMBL1365830 | 0.79 | ADAM10 (1.00) | ADAM10MMP2ERBB2MMP9CTSB | |
| SCHEMBL1365829 | 0.79 | ADAM10 (1.00) | ADAM10MMP2ERBB2MMP9CTSB | |
| SCHEMBL1365563 | 0.79 | ADAM10 (1.00) | ADAM10MMP2ERBB2MMP9CTSB | |
| SCHEMBL2172914 | 0.74 | ADAM10 (0.44) | ADAM10MMP2ERBB2MMP9GRM5 | |
| SCHEMBL2173773 | 0.72 | ADAM10 (0.70) | ADAM10MMP2ERBB2MMP9CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403775-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-7723349-B2 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | MMP9, MMP25, HDAC5 | ADAM10 258/4885MMP2 41/4885ERBB2 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.